SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Intas Pharma Ltd. (Amalgamated) (Amalgamated)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: Pharmaceuticals & Drugs | Small Cap | Intas Pharma(Amalgam Share Price

BSE Share Price
Not Listed

Intas Pharma Ltd. (Amalgamated) (Amalgamated)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: Pharmaceuticals & Drugs | Small Cap | Intas Pharma(Amalgam Share Price

BSE Share Price
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹0 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
₹0
TTM Sales
₹69.8 Cr.
Book Value per Share
-
P/E Ratio
0.00
Industry PE
49.8
Price to Book (P/B)
0.00
Price to Sales (P/S)
0.00
EV/EBITDA
0.00
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
-2.30%
Return on Capital Employed (ROCE)
5.68%
Return on Assets (ROA)
-0.44%
Operating Profit Margin
20.4%
Net Profit Margin
-1.52%
Gross Profit Margin
12.9%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
-
1416.52%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
%
Pledged shares (%) of Promoter's holding (%)
%
Reserves
₹50 Cr.
Equity
₹0 Cr.
Face Value
₹10
All Time Low / High
- / -

Intas Pharma . (Amalgamated) (Amalgamated) stock performance

Key Ratios
mw4me loader

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Mar'10Mar'11Mar'12TTM
ROCE % 0%-17.9%5.7%-

Growth Parameters

Sales 04.669.870
Sales YoY Gr.-NA1,416.5%-
Adj EPS 0-38.2-1.90
YoY Gr.-NANA-
BVPS (₹) -8.127.243.50
Adj Net
Profit
0-38.2-2.90
Cash Flow from Ops. 8.3-17.8-74.1-
Debt/CF from Ops. 15-6.9-2.2-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales NANANA1416.5%
Adj EPS NANANANA
BVPSNANANA59.9%
Share Price - - - -

Key Financial Parameters

Mar'10Mar'11Mar'12TTM
Return on
Equity %
0-182.1-6.30
Op. Profit
Mgn %
0-402.320.4NAN
Net Profit
Mgn %
0-829.9-4.10
Debt to
Equity
-314.52.5-
Working Cap
Days
01,6044470
Cash Conv.
Cycle
01,0721770

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'10Mar'11Mar'12
Sales04.6069.75
Operating Expenses + 023.3955.55
Manufacturing Costs06.578.68
Material Costs08.6532.98
Employee Cost 04.195.87
Other Costs 03.998.02
Operating Profit 0-18.7914.20
Operating Profit Margin (%) --408.0%20.4%
Other Income + 00.593.31
Exceptional Items 000
Interest 013.878.49
Depreciation 05.906.80
Profit Before Tax 0-37.972.22
Tax 00.083.28
Profit After Tax 0-38.06-1.06
PAT Margin (%) --827.0%-1.5%
Adjusted EPS (₹)0.0-38.1-0.7
Dividend Payout Ratio (%)0%0%0%

Valuation of Intas Pharma(Amalgam - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'10Mar'11Mar'12

Equity and Liabilities

Shareholders Fund + 14.7527.1965.23
Share Capital 4.951015
Reserves 9.8017.1950.23
Debt +124.53110.78148.55
Long Term Debt124.53110.78131.93
Short Term Debt0016.62
Minority Interest000
Trade Payables10.9134.3350.34
Others Liabilities 1.3713.2428.85
Total Liabilities 151.56185.55292.97

Fixed Assets

Net Fixed Assets +0153.55153.64
Gross Block0159.39166.26
Accumulated Depreciation05.8412.62
CWIP 124.1000
Investments 000
Inventories4.1122.6257.25
Trade Receivables06.1974.47
Cash Equivalents 0.080.170.14
Others Assets 23.273.027.47
Total Assets 151.56185.55292.97

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'10Mar'11Mar'12
Cash Flow From Operating Activity + 8.28-17.82-74.05
PBT 0-37.972.22
Adjustment 020.0515.35
Changes in Working Capital 8.130.1-91.62
Tax Paid 0.1500
Cash Flow From Investing Activity + -108.48-16.86-6.95
Capex -108.48-16.86-6.95
Net Investments 000
Others 0-00
Cash Flow From Financing Activity + 77.7134.5480.97
Net Proceeds from Shares 050.5050
Net Proceeds from Borrowing 77.7100
Interest Paid 0-13.87-8.49
Dividend Paid 000
Others 0-2.1039.46
Net Cash Flow -22.49-0.15-0.03

Financial Ratio

PARTICULARSMar'10Mar'11Mar'12
Ratios
ROE (%)0-328.42-2.3
ROCE (%)0-17.855.68
Asset Turnover Ratio00.030.29
PAT to CFO Conversion(x)N/AN/AN/A
Working Capital Days
Receivable Days0490.90211
Inventory Days01,060.40209
Payable Days0954.40468.50

Management X-Ray

Shareholding Pattern

No Data To Display

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Intas Pharma Ltd. (Amalgamated) (Amalgamated) FAQs

The current trading price of Intas Pharma(Amalgam on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Intas Pharma(Amalgam stood at ₹0.00 Cr

The latest P/E ratio of Intas Pharma(Amalgam as of 31-Dec-1969 is 0.00.

The latest P/B ratio of Intas Pharma(Amalgam as of 31-Dec-1969 is 0.00.

The 52-week high of Intas Pharma(Amalgam is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Intas Pharma(Amalgam is ₹69.75 ( Cr.) .

Data is not available for this company.

No data found

No data found

About Intas Pharma Ltd. (Amalgamated) (Amalgamated)

No data to display
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: